April 2022 - Page 2 of 4 - BioMedWire (BMW)

TuesdayApr 19, 2022 3:08 pm

AI Platform Reveals New Signatures of Parkinson’s Disease

Scientists have unveiled a new platform that can identify cellular signatures of illness by studying patient cells, using artificial intelligence (AI) methods for image analysis. Researchers at the New York Stem Cell Foundation Research Institute partnered with Google Research for the study, which involved the identification of new cellular characteristics of Parkinson’s disease through the creation and profiling of millions of skin cell images. These cells were obtained from a cohort of 91 patients and healthy individuals, who were the control group. Parkinson’s disease is a progressive brain disorder that impacts an individual’s movement. The disease’s symptoms usually begin gradually,…

MondayApr 18, 2022 10:56 am

Study Finds That Plant-Based Diets Lower Risk of Developing Type 2 Diabetes

A new study has found that consuming a healthy plant-based diet of legumes, nuts, vegetables, fruits and coffee is linked to a lower risk of developing type 2 diabetes. Healthy plant-based diets are rich in high-quality foods such as whole grains, vegetables and fruits. These diets have been linked to a lower risk of type 2 diabetes. Type 2 diabetes presents a major threat to health across the globe given that more than 90% of people with diabetes suffer from type 2 diabetes. Diabetes is mainly caused by unhealthy diets and genetic predisposition as well as being obese or overweight…

MondayApr 18, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent application Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods," further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs. The application covers an array of inhalation delivery…

ThursdayApr 14, 2022 3:46 pm

Study Finds Malnutrition Linked to Decline in Kidney Function in Older Individuals

A new study has found that malnutrition is associated with chronic kidney disease, increased risk of kidney function decline and poor kidney function in older adults who don’t suffer from advanced kidney disease. Chronic kidney disease, which is sometimes referred to as chronic kidney failure, occurs when an individual’s kidneys gradually lose function and fail to filter blood as they should. Treatment for this disease is focused on slowing the progression of damage to the kidneys, which isn’t easy to do if the disease has already advanced to end-stage kidney failure. The study was conducted by researchers at the Cheeloo…

WednesdayApr 13, 2022 1:38 pm

Research Emphasizes Importance of Screening for Unhealthy Consumption of Alcohol

New research has found that during primary care visits, screening for unhealthy consumption of alcohol by patients through the use of a validated questionnaire is rarely done. This is despite the current recommendations provided by the U.S. Preventive Services Task Force. Figures show that between 2014 and 2016, screening was performed during only about 3% of office visits. Brittany Charrerton, a research fellow in the Department of Internal Medicine, stated that primary care physicians were usually overwhelmed with many patient health concerns and sometimes performing screening for alcohol consumption of patients was forgotten. Data from the National Institute on Alcohol…

WednesdayApr 13, 2022 9:00 am

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”) CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there The study…

TuesdayApr 12, 2022 1:28 pm

University of Virginia Cancer Center Helps Update National Brain Cancer Treatment Guidelines

Around 700,000 Americans are estimated to live with brain cancer, and by the end of 2022, nearly 90,000 more will have been diagnosed with the deadly disease. In 2020, brain and Central Nervous System (CNS) tumors took more than 200,000 lives worldwide. It is a debilitating condition that can significantly reduce a patient and their family’s quality of life. The most common treatment methods for brain cancer are surgery, chemotherapy and radiation. While these treatment options can allow people with brain tumors to live for years after they are diagnosed, they aren’t risk free. Chemotherapy and radiation, for instance, cause…

TuesdayApr 12, 2022 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa) The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion…

TuesdayApr 12, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in 2021 With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022 Founded in 2020, Mydecine Innovations Group (NEO: MYCO)…

MondayApr 11, 2022 2:29 pm

Study Links Excessive Napping to Increased Risk of Developing Alzheimer’s

New research has found that excessive napping in the daytime for older individuals may indicate a heightened risk of Alzheimer’s disease. The study, which involved a cohort of older individuals, was carried out by researchers at Brigham and Women’s Hospital. The researchers discovered a link between cognitive aging and excessive napping in the daytime, noting that being diagnosed with Alzheimer’s accelerated the increase in daytime napping as an individual aged while excessive napping during the daytime forecasted an elevated future risk of Alzheimer’s. The study’s findings were reported in “Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association.” Peng Li,…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: April 2022

AI Platform Reveals New Signatures of Parkinson’s Disease

Study Finds That Plant-Based Diets Lower Risk of Developing Type 2 Diabetes

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

Study Finds Malnutrition Linked to Decline in Kidney Function in Older Individuals

Research Emphasizes Importance of Screening for Unhealthy Consumption of Alcohol

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

University of Virginia Cancer Center Helps Update National Brain Cancer Treatment Guidelines

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

Study Links Excessive Napping to Increased Risk of Developing Alzheimer’s

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search